Information Provided By: 
Fly News Breaks for May 16, 2017
IONS, PRTA
May 16, 2017 | 07:45 EDT
SunTrust analyst Yun Zhong says that safety issues with Ionis' inotersen during a Phase III trial are positive for Prothena. The analyst says that Prothena's new drug, PRX004, could have a better safety profile than its previous drug, NEOD001,. He notes that PRX004 has a different mechanism of action than Ionis' drug, and he thinks the discrepancy could enable Prthena's drug to have a better safety profile. He keeps a Buy rating on Prothena.
News For PRTA;IONS From the Last 2 Days
There are no results for your query PRTA;IONS
